TaiMed Biologics (ROCO:4147) Tariff Resilience Score: 0/10 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4147 TaiMed Biologics Inc ROCO:4147
55 GF Score
Price NT$58.90
GF Value NT$86.12
Valuation Significantly Undervalued
View Full Analysis

What is TaiMed Biologics Tariff Resilience Score?

TaiMed Biologics has the Tariff Resilience Score of 0, which implies that the company might have .

TaiMed Biologics has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes TaiMed Biologics might have .


TaiMed Biologics  (ROCO:4147) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

TaiMed Biologics Tariff Resilience Score Related Terms

ROCO:4147
55GF Score
TaiMed Biologics Inc ROCO:4147
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?

Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued. The current stock price of NT$58.90 is trading 31.6% below its estimated GF Value™ of NT$86.12. GuruFocus considers TaiMed Biologics to be Significantly Undervalued.

Key valuation signals for ROCO:4147:

  • Tariff Resilience Score: 0
  • GF Value™: NT$86.12 vs. price of NT$58.90 (31.6% below fair value)
  • GF Score™: 55/100

No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TaiMed Biologics Business Description

Address No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score

Get the complete analysis for ROCO:4147

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$58.90
Price
NT$86.12
GF Value